Choosing appropriate pharmacotherapy for drug-resistant HIV

References

• Mansky LM. HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updat. 2002;5(6):219–223. PubMed: 12531178.
   PubMed Web of Science ®Google Scholar
• Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105(21):7552–7557. PubMed: 18490657.
   PubMed Web of Science ®Google Scholar
• Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267(5197):483–489. PubMed: 7824947.
   PubMed Web of Science ®Google Scholar
• Levy DN, Aldrovandi GM, Kutsch O, et al. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A. 2004;101(12):4204–4209. PubMed: 15010526.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med . 2006;3(9):e356. PubMed: 19684218.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009;151(2):73–84. PubMed19620160.
   PubMed Web of Science ®Google Scholar
• Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis. 2009;13(5):552–559. PubMed: 15010526.
   PubMed Web of Science ®Google Scholar
• Kassaye SG, Grossman Z, Balamane M, et al. Transmitted HIV drug resistance is high and longstanding in metropolitan Washington, DC. Clin Infect Dis. 2016 Sep 15;63(6):836–843. PubMed: 27307507.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr 7;12(4):e1001810. PubMed: 25849352. eCollection 2015 Apr .
   PubMed Web of Science ®Google Scholar
• Pence BW, Mills JC, Bengtson AM, et al. Association of increased chronicity of depression with hiv appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry. 2018 Feb 21. PubMed: 29466531 DOI:10.1001/jamapsychiatry.2017.4726.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim SW, Chang HH, et al. Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching. Infect Chemother. 2015 Dec;47(4):231–238. PubMed: 26788406. Epub 2015 Dec 30.
   PubMed Web of Science ®Google Scholar
• Hojilla JC, Vlahov D, Glidden DV, et al. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. J Int AIDS Soc. 2018 Mar;21(3):e25103. PubMed: 29577616.
   PubMed Web of Science ®Google Scholar
• Edmundson C, Heinsbroek E, Glass R, et al. Sexualised drug use in the United Kingdom (UK): a review of the literature. Int J Drug Policy. 2018 Apr 3;pii: S0955-3959(18)30037–9. PubMed: 29625796. Epub ahead of print. DOI:10.1016/j.drugpo.2018.02.002.
   Web of Science ®Google Scholar
• Olson A, Bannert N, Sönnerborg A, et al. Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. AIDS. 2018 Jan 14;32(2):161–169. PubMed: 29112061.
   PubMed Web of Science ®Google Scholar
• WHO HIV Drug Resistance Report 2017. [cited 2018 April 28]. Available from: http://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf;jsessionid=44D61524884917F45757DA2956B3D546?sequence=1
   Google Scholar
• Coetzee JM, Hunt G, Jaffer M, et al. HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS One. 2017 Dec 15; 12(12):e0188606. PubMed: 2294809. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Brenner BG, Ibanescu RI, Hardy I, et al. Genotypic and phylogenetic insights on prevention of the spread of HIV-1 and drug resistance in “real-world” settings. Viruses. 2017 Dec 28;10(1):E10. PubMed: 29283390.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. [cited 2018 Apr 28]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection recommendations for a public health approach second edition. 2016 [cited 2018 Apr 28]. Available from: www.who.int/hiv/pub/arv/arv-2016/en/.
   Google Scholar
• Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012 Feb;251:17–25. PubMed: 22156900. Review.
   PubMed Web of Science ®Google Scholar
• D’Arminio-Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study group. Italian cohort of antiretroviral-naive patients. AIDS. 2000;14(5):499–507. PubMed: 10780712.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15(2):185–194.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183. PubMed: 11416722.
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Chalmers L, Bereznicki LR, et al. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore). 2016;95(15):e3361. PubMed: 27082595.
   PubMed Web of Science ®Google Scholar
• Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among hiv-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017;17(1):326. PubMed: 28468608.
   PubMedGoogle Scholar
• Patel N, Borg P, Haubrich R, et al. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm. 2018;75(15)1132–1139. PubMed: 29903710. Epub [2018 Jun 14].
   PubMed Web of Science ®Google Scholar
• Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47(11):1429–1439. PubMed: 24285760.
   PubMed Web of Science ®Google Scholar
• Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS. 2017 Jun 1;31(Suppl 2):S173–S184.
   PubMedGoogle Scholar
• Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study. Antivir Ther. 2010;15(3):413–423. PubMed: 20516560.
   PubMed Web of Science ®Google Scholar
• Molas E, Luque S, Retamero A. et al. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary team. HIV Clin Trials. 2018; 19(1):1–7. PubMed: 29179644. Epub 2017 Nov 28.
   PubMed Web of Science ®Google Scholar
• Pillay B, Wootten AC, Crowe H et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. PubMed: 26643552. Epub 2015 Nov 24.
   PubMed Web of Science ®Google Scholar
• Mathis S, Khanlari B, Pulido F. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003. PubMed: 21811554. Epub 2011 Jul 19.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Le Fevre E, Carr A, et al. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS. 2016 May 15;30(8):1229–1238. PubMed: 26854810.
   PubMed Web of Science ®Google Scholar
• Pulido I, Genebat M, Alvarez-Rios AI, et al. Immunovirological efficacy of once-daily maraviroc plus ritonavir-boosted atazanavir after 48 weeks in naive HIV-infected patients. Viral Immunol. 2016 Oct;29(8):471–477. PubMed: 27689417. Epub 2016 Sep 22.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Oldenbuettel C, Thomas R, et al. Pathways of resistance in subjects failing dolutegravir monotherapy. In: Conference on retroviruses and opportunistic infections. Seattle, USA; 2017.
   Google Scholar
• Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012 Jun 18;72(9):e1–e25. PubMed: 22686620.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Pulido F, García F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015 Jan-Mar;17(1):56–64. PubMed: 25472016.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Marcelin AG, Katlama C, et al. Dolutegravir resistance mutations: lessons from monotherapy studies. Curr Opin Infect Dis. 2018 Jun;31(3):237–245.
   PubMed Web of Science ®Google Scholar
• Wijting IEA, Lungu C, Rijnders BJA, et al. HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy. J Infect Dis. 2018 Mar 29. PubMed: 29617822. Epub ahead of print. DOI:10.1093/infdis/jiy176.
   Web of Science ®Google Scholar
• Shen L, Peterson S, Ar S, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008 Jul;14(7):762–766. PubMed: 18552857. Epub 2008 Jun 15.
   PubMed Web of Science ®Google Scholar
• Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci. 2009 Dec;30(12):610–616. PubMed: 19837466.
   PubMed Web of Science ®Google Scholar
• Andrade A, Guedj J, Rosenkranz SL, et al. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids. 2015 Nov 28;29(18):2419–2426. PubMed: 26558541.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015 Apr; 2(4):e127–36. PubMed: 26424673. Epub 2015 Mar 10. Erratum in: Lancet HIV. 2015 Apr;2(4):e126. DOI: 10.1016/S2352-3018(15)00027-2.
   PubMed Web of Science ®Google Scholar
• Sampah ME, Shen L, Jilek BL et al. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7613–7618. PubMed: 21502494. Epub 2011 Apr 18.
   PubMed Web of Science ®Google Scholar
• Chang S, Zhuang D, Guo W, et al. The antiviral activity of approved and novel drugs against HIV-1 mutations evaluated under the consideration of dose-response curve slope. PLoS One. 2016 Mar 1;11(3):e0149467. PubMed: 26930645.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Colson AE, Sheble-Hall AG. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials. 2007 Jan-Feb;8(1):19–23. PubMed: 17434845.
   PubMed Web of Science ®Google Scholar
• Elliot ER, Amara A, Pagani N, et al. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72?h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. J Antimicrob Chemother. 2017 Jul 1;72(7):2035–2041. PubMed: 28407075.
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Fletcher C, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2009 Apr;53(4):1532–1538. PubMed: 28407075. Epub 2009 Feb 2.
   PubMed Web of Science ®Google Scholar
• Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443–1450. PubMed: 23600365.
   PubMed Web of Science ®Google Scholar
• Hemmige V, Flash CA, Carter J, et al. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients. AIDS Care. 2018 Feb 25: 1–8. PubMed: 29478329. Epub ahead of print. doi: 10.1080/09540121.2018.1442554.
   Web of Science ®Google Scholar
• Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, et al. Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients. Fundam Clin Pharmacol. 2018 Mar 5;32:450–458. PubMed: 29505661. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Al-Dakkak I, Patel S, McCann E, et al. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400–414. PubMed: 22908886.
   PubMed Web of Science ®Google Scholar
• Li H, Marley G, Ma W, et al. The role of ARV associated adverse drug reactions in influencing adherence among hiv-infected individuals: a systematic review and qualitative meta-synthesis. AIDS Behav. 2017 Feb;21(2):341–351. PubMed: 27613645. DOI:10.1007/s10461-016-1545-0.
   PubMed Web of Science ®Google Scholar
• Kanters S, Me S, Paton NI, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017 Oct 4; 4(10): e433–e441. PubMed 28784426. Epub 2017 Aug.
   PubMed Web of Science ®Google Scholar
• Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489–493. PubMed 22293546.
   PubMed Web of Science ®Google Scholar
• Tashima KT, Mollan KR, Na L, et al. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015 Aug;16(4):147–156. PubMed 26212575. Epub 2015 Jul 27.
   PubMed Web of Science ®Google Scholar
• Arastéh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859–864. PubMed 19812449.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013 Jul;13(7):587–596. PubMed 23664333. Epub 2013 May 7.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Aug 24;382(9893):700–708. PubMed :23830355. Epub 2013 Jul 3.
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014 Aug 1; 210(3): 354–362. PubMed: 24446523. Epub 2014 Jan 19.
   PubMed Web of Science ®Google Scholar
• Lewis S, Fessel J, Emu B, et al. Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study. In: Conference on retroviruses and opportunistic infections. Seattle, USA; 2017.
   Google Scholar
• Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215–223. PubMed 27922453. Epub 2016 Dec 6.
   PubMed Web of Science ®Google Scholar
• Kozal M, Aberg J, Pialoux G, et al. Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1-infected participants: day 8 and week 24 primary efficacy and safety results (BRIGHTE study, formerly 205888/AI438-047). EACS - 16th European AIDS Conference; 2017 October 25-27; Milan, Italy.
   Google Scholar
• Capetti AF, Cossu MV, Sterrantino G, et al. Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data. Ann Pharmacother. 2018 Feb 1;1060028018761600. PubMed: 29482352. Epub ahead of print. DOI:10.1177/1060028018761600.
   Web of Science ®Google Scholar
• Palacios R, Mayorga M, Gonzalez-Domenech CM, et al. Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care.Jan-Dec 2018;17:2325958218760847. PubMed: 29529910.
   Google Scholar
• Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, et al. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2017 Aug 1;1060028017728294. PubMed: 28836468. Epub ahead of print. DOI:10.1177/1060028017728294.
   Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Orofino G, et al. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data. BMC Infect Dis. 2017 Sep 30; 17(1):658. PubMed: 28964268.
   PubMedGoogle Scholar
• Castagna A, Ferrara M, Galli L, et al. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. J Antimicrob Chemother. 2018 Jan 1;73(1):177–182. PubMed 29077927.
   PubMed Web of Science ®Google Scholar
• Biscione FM, Westin MR, Ribeiro KM, et al. Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort. J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):63–68. PubMed: 24134962. Epub 2013 Oct 17.
   PubMedGoogle Scholar
• Poveda E, Blanco F, García-Gascó P, et al. Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. AIDS. 2006 Jul 13;20(11):1558–1560. PubMed: 16847414.
   PubMed Web of Science ®Google Scholar
• Landry S, Chen CN, Patel N, et al. Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series. Antiviral Res. 2018 Apr;152:111–116. PubMed: 29458132. Epub 2018 Feb 17.
   PubMed Web of Science ®Google Scholar
• Domínguez-Hermosillo JC, Mata-Marin JA, Herrera-González NE, et al. Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients. J Infect Dev Ctries. 2016 Sep 30;10(9):982–987. PubMed: 27694731.
   PubMed Web of Science ®Google Scholar
• Bernardino JI, Zamora FX, Valencia E, et al. Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19787. PubMed: 25397531. eCollection 2014.
   PubMedGoogle Scholar
• Huerta García G, Mata-Marín JA, Domínguez-Hermosillo JC, et al. Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients. J Infect Dev Ctries. 2016 Jun 30;10(6):605–611. PubMed: 27367009.
   PubMed Web of Science ®Google Scholar
• Osterholzer D. The role of etravirine in the management of treatment-experienced pediatric patients with HIV. HIV AIDS (Auckl). 2013 Apr 10;5:67–73. PubMed: 23610529. Print 2013.
   PubMedGoogle Scholar
• Saumoy M, Llibre JM, Terrón A, et al. Short communication: maraviroc once-daily: experience in routine clinical practice. AIDS Res Hum Retroviruses. 2017 Jan;33(1):29–32. PubMed: 27250802. Epub 2016 Dec 20.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Astuti N, Landonio S, et al. Durability of boosted atazanavir (ATV) or darunavir (DRV) plus maraviroc (MVC) dual rescue therapy in poorly adherent subjects in view of long-acting drugs. J Antivir Antiretrovir. 2017;9(4):167.
   Google Scholar
• Nozza S, Galli L, Bigoloni A, et al. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine. New Microbiol. 2014 Apr;37(2):145–151. PubMed: 24858641. Epub 2014 Apr 1.
   PubMed Web of Science ®Google Scholar
• De Gruttola V, Flexner C, Schapiro J, et al. Drug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses. 2006;22:1106–1109.
   PubMed Web of Science ®Google Scholar
• Lederman M, Miller V, Weller I, et al. A new approach for ‘deep salvage’ trials in advanced HIV infection. AIDS. 2007;21(12):1503–1506.
   PubMed Web of Science ®Google Scholar
• Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F, et al. Historical resistance profile helps to predict salvage failure. Antivir Ther. 2009;14(2):285–291. PubMed: 19430103.
   PubMed Web of Science ®Google Scholar
• Wirden M, Soulie C, Valantin MA, et al. HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother. 2011 Apr;66(4):709–712. PubMed: 21393164. Epub 2011 Jan 26.
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Braun J, Charreau I, et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med. 2012 Oct;13(9):517–525. PubMed. 2241678. Epub 2012 Mar 14.
   PubMed Web of Science ®Google Scholar
• Beerenwinkel N, Montazeri H, Schuhmacher H, et al. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol. 2013;9(8):e1003203. PubMed: 24009493. Epub 2013 Aug 29.
   PubMed Web of Science ®Google Scholar
• Bader J, Däumer M, Schöni-Affolter F, et al. Therapeutic immune recovery and reduction of CXCR4-Tropic HIV-1. Clin Infect Dis. 2017 Feb 1;64(3):295–300. PubMed: 27838645. Epub 2016 Nov 12.
   PubMed Web of Science ®Google Scholar
• Delory T, Papot E, Rioux C, et al. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience. J Med Virol. 2016 Jul;88(7):1204–1210. PubMed: 26636432. Epub 2016 Jan 5.
   PubMed Web of Science ®Google Scholar
• Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018 Jan 5; 13(1):e0190487. PubMed 29304154. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Grobler J, Friedman E, Barrett SE, et al. Long-acting oral and parenteral dosing of mk-8591 for hiv treatment or prophylaxis. Conference on retroviruses and opportunistic infections; Boston, USA; 2018.
   Google Scholar
• Barrett SE, Teller RS, Forster SP, et al. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01058–18.
   PubMed Web of Science ®Google Scholar
• Theys K, Camacho RJ, Gomes P, et al. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Clin Microbiol Infect. 2015 Jun;21(6):607.e1–8. PubMed: 25704446. Epub 2015 Feb 19.
   PubMed Web of Science ®Google Scholar
• Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017 Jun 5;14(1):36. PubMed: 2858319.
   PubMedGoogle Scholar
• Theys K, Van Laethem K, Gomes P, et al. Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive hiv-1-infected patients: subtype and geographic compartmentalization of baseline resistance mutations. AIDS Res Hum Retroviruses. 2016 May;32(5):427–433. PubMed: 26651266. Epub 2016 Jan 29.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12(4): 563–570. PubMed: 17668566.
   PubMed Web of Science ®Google Scholar
• Varghese V, Liu TF, Rhee SY, et al. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010 Dec;26(12):1323–1326. PubMed: 20961278. Epub 2010 Oct 21.
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Kodama E, Sarafianos SG, et al. 2’-deoxy-4’-C-ethynyl-2-halo-adenosines active against drug-resistant humanimmunodeficiency virus type 1 variants. Int J Biochem Cell Biol. 2008;40(11)2410–2420. PubMed: 18487070. Epub 2008 Apr 11.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Brenner BG, Xu H, et al. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. J Antimicrob Chemother. 2017;72(11):3008–3011. PubMed: 28961903.
   PubMed Web of Science ®Google Scholar
• Mpondo BC, HIV infection in the elderly: arising challenges. J Aging Res. 2016;2016:2404857. PubMed: 27595022. Epub Aug 9.
   PubMedGoogle Scholar
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. [cited 2018 May 9]. Available from: https://aidsinfo.nih.gov/guidelines/html/3/perinatal/489/table-9--arv-drug-use-in-pregnant-hiv-infected-women
   Google Scholar
• Datta D, Moyle G, Mandalia S, et al. Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV Med. 2003 Oct;4(4):311–314. PubMed: 14525541.
   PubMedGoogle Scholar
• Duryea E, Nicholson F, Cooper S, et al. The use of protease inhibitors in pregnancy: maternal and fetal considerations. Infect Dis Obstet Gynecol. 2015;2015:563727. PubMed: 26617456.
   PubMedGoogle Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017 Jan;56(1):25–40. PubMed: 27317415 DOI: 10.1007/s40262-016-0424-1. Review
   PubMed Web of Science ®Google Scholar
• Khoo S, Peytavin G, Burger D, et al. Pharmacokinetics and safety of darunavir/ritonavir in hiv-infected pregnant women. AIDS Rev. 2017 Jan-Mar;19(1):16–23. PubMed: 28182610.
   PubMed Web of Science ®Google Scholar
• Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018 Sep 6;379(10):979–981. Epub 2018 Jul 24.
   PubMed Web of Science ®Google Scholar
• Weidle PJ, Nesheim S. HIV drug resistance and mother-to-child transmission of HIV. Clin Perinatol. 2010 Dec;37(4):825–42, x. PubMed: 21078453.
   PubMed Web of Science ®Google Scholar
• Boerma RS, Bunupuradah T, Dow D, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. J Int AIDS Soc. 2017 Sep 15;20(1):21930. PubMed: 28953325.
   PubMedGoogle Scholar
• Pironti A, Pfeifer N, Walter H, et al. Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool. PLoS One. 2017 Apr 10;12(4):e0174992. PubMed: 28394945. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• FDA approval letter for Juluca (dolutegravir plus rilpivirine). [cited 2018 Oct 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210192Orig1s000Approv.pdf
   Google Scholar
• Cahn P, Sierra-Madero J, Arribas J et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) vs DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve adults with HIV-1 infection – week 48 Results from the Gemini Studies. 22nd International AIDS Conference; 2018 July 23-27; Amsterdam,The Netherlands.
   Google Scholar
• Kuhlmann A, Mittendorf T, Hower M, et al. Cost of illness of hiv patients under anteretroviral therapy in Germany - results of the 48 week interim analysis of the prospective multicentre observational study ‘CORSAR’. Gesundheitswesen. 2015 Jun;77(6):e133–e142. PubMed: 25247761. Epub 2014 Sep 23.
   PubMed Web of Science ®Google Scholar
• Evans D, Hirasen K, Berhanu R, et al. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 Apr 10; 15(1):10. PubMed: 29636106.
   PubMedGoogle Scholar